Lymphoma/Leukemia News

Study Yields Clues Into Different Leukemia Forms And Possible Therapeutic Targets

Sun, 22 Jun 2008 19:00:04 GMT

Research led by scientists at Cincinnati Children's Hospital Medical Center has revealed new clues into what causes different types of a particularly aggressive group of blood cancers known as mixed lineage leukemias (MLL) and how the disease might be treated, according to a study in Cancer Cell.

Full text

MicroRNA Controls Expression Of Oncogenes

Sun, 22 Jun 2008 19:00:04 GMT

A new study demonstrates that microRNAs can modulate the expression of well known tumor-specific oncogenic translocation proteins and may play a significant role in some human cancers.

Full text

Pharmacyclics Novel Btk Inhibitor Shows Efficacy In Preclinical Models Of Rheumatoid Arthritis And Lymphoma

Sat, 21 Jun 2008 15:40:06 GMT

Pharmacyclics, Inc. (Nasdaq: PCYC) announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal model for rheumatoid arthritis (RA).

Full text

Math Could Help Cure Leukemia

Sat, 21 Jun 2008 15:40:02 GMT

When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer.

Full text

Results Of A Phase 3 Study Show TORISEL Significantly Improved Progression-free Survival For Patients With Relapsed refractory Mantle Cell Lymphoma

Fri, 20 Jun 2008 11:40:06 GMT

Data presented from a phase 3 clinical trial at the 44th Annual Meeting of the American Society of Clinical Oncology show that patients with relapsed and/or refractory (failed front line therapy and unresponsive to most recent treatment) mantle cell lymphoma (MCL) treated with TORISEL (temsirolim.

Full text

Galiximab In Combination With Rituximab In Patients With Previously Untreated Follicular Lymphoma

Fri, 20 Jun 2008 11:40:05 GMT

The Cancer and Leukemia Group B (CALGB) has announced data from a phase II clinical trial showing that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab, an investigational anti-CD80 monoclonal antibody, when given in combination with rituximab.

Full text

Individualized Therapies For Non-Hodgkin's Lymphoma

Fri, 20 Jun 2008 11:40:04 GMT

Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT) - the first radioimmunotherapy treatment approved for use by the U.

Full text

Ability To Track Stem Cells In Tumors Could Advance Cancer Treatments

Fri, 20 Jun 2008 11:40:03 GMT

Using noninvasive molecular imaging technology, a method has been developed to track the location and activity of mesenchymal stem cells (MSCs) in the tumors of living organisms, according to researchers at SNM's 55th Annual Meeting.

Full text

England Footballer Geoff Thomas Demands Government Funding To Beat Leukeamia

Wed, 18 Jun 2008 04:41:36 GMT

Former England footballer, Geoff Thomas is pressing the Government for urgently needed cash to develop and deliver new leukaemia treatments.

Full text

Micromet's BiTE Antibody Blinatumomab MT103 MEDI-538 Demonstrates Durable Responses In Patients With Relapsed Non-Hodgkin's Lymphoma

Wed, 18 Jun 2008 04:40:37 GMT

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland.

Full text